Fig 1: Sorafenib treatment enhances SHP-1 activity, inactivates STAT3, reduces MCL1 expression, and triggers ferroptosis in the Huh7 murine model: (A) Sorafenib inhibited tumor growth in Huh7 tumor-bearing mice. Sorafenib was orally administered five times per week, and the tumor volumes were measured twice weekly. Points: mean; bars: standard error of the mean (SEM) (n = 7). Statistical significance was evaluated by two-way ANOVA (*, p < 0.05; ***, p < 0.001). (B) At the end of the treatment, the Huh7 tumors were excised, and the tumor weights were recorded. (C) SHP-1 activities were measured using Huh7 tumor lysates from the mice treated with sorafenib or vehicle. (D) Total GSH levels and (E) MDA levels were evaluated using Huh7 tumors collected from the mice treated with sorafenib. (F) The protein expression levels (upper panel) and the quantification results (lower panel) of p-STAT3 (Y705), STAT3, MCL1, BECN1, and 4-HNE adducts were examined via Huh7 tumor lysates acquired from sorafenib-treated mice. Columns: mean; bars: SD (n = 7). Statistical significance was determined by using the Mann–Whitney U test (*, p < 0.05; **, p < 0.01; ***, p < 0.001).